PER® Miami Breast Cancer Conference | Conference

Dr. Carey on Treating Triple-Negative Breast Cancer

February 28th 2015

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Early Intervention Essential for Proper Lymphedema Management

February 27th 2015

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Driver Mutations Remain Prognostic But Not Predictive in Breast Cancer

February 27th 2015

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

Neoadjuvant Endocrine Therapy Appropriate in Select Patients

February 27th 2015

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

Excitement Building for PARP Inhibitors in BRCA-Mutated Breast Cancer

February 27th 2015

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

Dr. Tripathy on the Possibility of Curing Metastatic Breast Cancer

February 26th 2015

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

Dr. Attai on What Physicians Can Learn from Social Media

February 26th 2015

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, explains how social media can help physicians.

MBCC Embraces Revolution in Breast Cancer Care

February 26th 2015

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

Three Experts Examine the ER-Positive Treatment Landscape

February 26th 2015

With the evolution of treatment under way, OncLive interviewed three world-renowned experts in the field: Joanne L. Blum, MD, PhD, Adam M. Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD.

Dr. Salerno on the Importance of Clinical Researchers

March 12th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses federal funding for research and the importance of gaining funds though private philanthropy to support clinical researchers.

New Trial Models Aim to Accelerate Pace of Neoadjuvant Approvals

March 10th 2014

New models have emerged for examining novel breast cancer treatments in the neoadjuvant setting that avoid the lengthy process of standard, large adjuvant trials.

New Developments on Horizon in HER2-Positive Breast Cancer

March 10th 2014

In the last decade, there have been tremendous improvements in the treatment of HER2-positive breast cancer with new HER2-targeted agents improving survival in both the adjuvant and metastatic settings.

Trastuzumab/Eribulin Combo Safe and Effective in HER2-Positive Breast Cancer

March 10th 2014

The first-line combination of trastuzumab and eribulin mesylate demonstrated an ORR of 71.2% with a median PFS of 11.6 months in patients with HER2-positive advanced breast cancer.

Ellen Matloff on Oophorectomy Timing for BRCA Carriers

March 10th 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

Dr. Verma on the Future of HER2-Positive Breast Cancer

March 8th 2014

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, provides an outlook on the treatment of HER2-positive breast cancer.

Emerging DCIS Strategies Look Beyond Surgery

March 8th 2014

Success rates for lumpectomies or mastectomies are high with respect to survival, with up to 98% long-term survival rates for surgery and/or radiotherapy, but what if similar results could be achieved by substituting targeted medications for therapy?

What's Ahead for BRCA Genetic Testing and Counseling?

March 8th 2014

The US Supreme Court's landmark decision last June, mandating that an individual's genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.

Next-Generation Sequencing Revolutionizes Discovery of Novel Targeted Therapies in Breast Cancer

March 8th 2014

The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.

Dr. Tripathy on Adjuvant Bisphosphonates in BC

March 7th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.

Dr. Boughey on Surgical Resection of Stage IV BC

March 7th 2014

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.